Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.

[1]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[2]  S. Nonen,et al.  Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .

[4]  M. Fukuoka,et al.  Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Hochstrasser,et al.  Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety , 2010, British journal of pharmacology.

[6]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[7]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[8]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[9]  D. Hochstrasser,et al.  Genetic polymorphisms and drug interactions modulating CYP 2 D 6 and CYP 3 A activities have a major effect on oxycodone analgesic efficacy and safetybph , 2010 .

[10]  R. Andrade,et al.  Pharmacogenomics in drug induced liver injury. , 2009, Current drug metabolism.

[11]  M. Cameron,et al.  Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. , 2009, Chemical research in toxicology.

[12]  N. Rizzo-Padoin,et al.  Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. , 2009, British journal of clinical pharmacology.

[13]  S. Zhan,et al.  Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  Shufeng Zhou,et al.  Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring , 2007, Therapeutic drug monitoring.

[15]  M. Hidalgo,et al.  Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes , 2007, Clinical Cancer Research.

[16]  Manuel Hidalgo,et al.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.

[17]  K. Uematsu,et al.  Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Swaisland,et al.  Exploring the Relationship Between Expression of Cytochrome P450 Enzymes and Gefitinib Pharmacokinetics , 2006, Clinical pharmacokinetics.

[19]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[20]  G. S. Miles,et al.  Cytochrome P450-dependent metabolism of gefitinib , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  J. Azuma,et al.  The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution. , 2005, Drug metabolism and pharmacokinetics.

[22]  M. Ranson,et al.  Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol , 2005, Clinical pharmacokinetics.

[23]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[24]  Julie A. Johnson,et al.  Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms , 2004, Journal of clinical pharmacology.

[25]  S. Steinberg,et al.  Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Tanikawa,et al.  Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Kitada.  Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. , 2003, International journal of clinical pharmacology research.

[29]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[30]  J. Azuma,et al.  CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. , 2000, Pharmacogenetics.

[31]  M. Ingelman-Sundberg,et al.  PCR-based genotyping for duplicated and deleted CYP2D6 genes. , 1996, Pharmacogenetics.

[32]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[33]  O. Andreassen,et al.  Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. , 1995, Pharmacogenetics.

[34]  S. Sherlock,et al.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury. , 1984, Gut.

[35]  M. Hidalgo,et al.  CYP 3 A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors , 2022 .